Butterfly Network (BFLY) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.01
- Estimate
- -$0.04
- Surprise
- +72.7%
- Revenue (period 2026-06-30)
- $32.6M
- Score at report (before → after)
- 4.9 → 5.0/10
Revenue source: xbrl.
How the report landed
Butterfly Network (BFLY) reported a narrower loss than forecast — adjusted EPS of -$0.01 against the -$0.04 estimate (a 72.7% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Sell (4.9/10) to Hold at 5.0/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BFLY Buy (Wait) at 5.8/10.
4 of the last 4 quarters beat the estimate; this quarter's +72.7% surprise compares with a +45.6% four-quarter average. Next scheduled report: 2026-10-29.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong growth profile
What argues against it
- Concentration risk — Supplier: TSMC
- Concentration risk — Supplier: Benchmark
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.3)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $6.96
- Entry target
- $6.56
- Price target
- $9.72
- Stop
- $6.10
- Upside to target
- +39.7%
- Reward-to-risk
- 3.0:1
Model outputs from TrendMatrix’s engine as of 2026-10-27 — shown for context, not personalized investment advice.
BFLY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $1.77B
- P/E (fwd)
- -98.7
- 52-week range
- $1.90–$10.21
- Off 52-week high
- 31.8%
- RSI (14)
- 33
- Volume vs avg
- 0.07×
- Score today
- 5.8/10